No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:05:23.295Z. Latest historical point 2023-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Adicet Bio, Inc. (ACET) stock was $6.46 as of Oct 6, 2026, 10:03 AM EDT, down 0.15% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -51.4% · 3-year avg -32.6%/yr · 5-year avg -44.2%/yr
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases.
Biotechnology · Boston, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2017-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2017-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-1.56
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.99
vs Estimate
$-1.64
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACET | $60.39M | $6.46 | -0.15% | -51.37% | -44.24% | N/A | N/A |
| 2GUTS | $59.56M | $4.50 | -1.21% | -75.32% | N/A | N/A | vs ACET |
| 3INKT | $59.32M | $11.91 | -2.40% | -18.69% | N/A | N/A | vs ACET |
| 4ALDX | $58.22M | $0.97 | +4.48% | -83.77% | -36.54% | -18.91% | vs ACET |
| 5KLRS | $62.97M | $2.88 | +1.94% | -57.21% | -81.13% | N/A | vs ACET |
| 6BOLD | $57.76M | $2.57 | -1.15% | +110.63% | N/A | N/A | vs ACET |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 6 analysts
Average Price Target
$34.83
+439.2% upside
Low
$18.00
Current
$6.46
High
$90.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.07 | $-1.58 | $-1.08 | 4 |
| Quarter ending Dec 2026 | $-2.04 | $-1.53 | $-1.02 | 4 |
| Quarter ending Mar 2027 | $-1.71 | $-1.71 | $-1.71 | 1 |
| Quarter ending Jun 2027 | $-1.67 | $-1.67 | $-1.67 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-7.57 | $-6.36 | $-5.14 | 4 |
| FY 2027 | $-5.49 | $-4.04 | $-2.59 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.86M | $2.86M | $2.86M | 6 |
| FY 2027 | $28.51M | $28.52M | $28.52M | 6 |
